Jane Kendrew

4.1k citations

33 papers · 2.7k indexed · 1 hit paper · h-index 22

Impact in

Oncology top 2%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
Cancer Research top 5%
- Cancer, Hypoxia, and Metabolism

Papers in ⓘ

Immunology and Allergy 5
- Cell Adhesion Molecules Research 5
Oncology 19
- HER2/EGFR in Cancer Research 8

Co-authors: Stephen R. Wedge (18 shared papers)Laurent Hennequin (10 shared papers)Jon Curwen (6 shared papers)Donald Ogilvie (10 shared papers)Elaine S. E. Stokes (5 shared papers)Michael Dukes (4 shared papers)Andrew P. Thomas (3 shared papers)Brenda J Curry (3 shared papers)
Journals: Molecular Cancer Therapeutics (7 papers)Clinical Cancer Research (3 papers)Cancer Research (3 papers)Bioorganic & Medicinal Chemistry Letters (2 papers)Journal of Medicinal Chemistry (2 papers)
Partner nations: United Kingdom France Singapore

In The Last Decade

Jane Kendrew

33 papers receiving 2.6k citations

Hit Papers

align trajectories log scale

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. 2002 · 702 citations

Peers

Countries citing papers authored by Jane Kendrew

Since Specialization

Citations

This map shows the geographic impact of Jane Kendrew's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane Kendrew with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane Kendrew more than expected).

Fields of papers citing papers by Jane Kendrew

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane Kendrew. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane Kendrew. The network helps show where Jane Kendrew may publish in the future.

Co-authors

The 25 scholars most cited alongside Jane Kendrew, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jane Kendrew Line = papers co-authored together Jane Kendrew links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. PubMed ·Stephen R. Wedge, Donald Ogilvie, Michael Dukes, Jane Kendrew, Rosemary Chester, Janet A. Jackson, Sarah J. Boffey, Paula J. Valentine, Jon Curwen, Helen Musgrove, George A Graham, Gareth Hughes, Andrew P. Thomas, Elaine S. E. Stokes, Brenda J Curry, Graham H.P. Richmond, P.F. Wadsworth, Alison Bigley, Laurent Hennequin Hit paper breakdown →	2002	702
2	Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors Journal of Medicinal Chemistry ·Laurent Hennequin, Elaine S. E. Stokes, Andrew P. Thomas, Craig Johnstone, Patrick A. Plé, Donald Ogilvie, Michael Dukes, Stephen R. Wedge, Jane Kendrew, Jon Curwen	2002	254
3	Design and Structure−Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors Journal of Medicinal Chemistry ·Laurent Hennequin, Andrew P. Thomas, Craig Johnstone, Elaine S. E. Stokes, Patrick A. Plé, Jean-Jacques M. Lohmann, Donald Ogilvie, Mike Dukes, Stephen R. Wedge, Jon Curwen, Jane Kendrew, Christine Lambert‐van der Brempt	1999	195
4	ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. PubMed ·Stephen R. Wedge, DJ Ogilvie, Michael Dukes, Jane Kendrew, Jon Curwen, Laurent Hennequin, A P Thomas, Elaine S. E. Stokes, Brenda J Curry, Ghp Richmond, P.F. Wadsworth	2000	157
5	Treatment with Soluble VEGF Receptor Reduces Disease Severity in Murine Collagen-Induced Arthritis Laboratory Investigation ·Jadwiga M. Miotla, Rose A. Maciewicz, Jane Kendrew, Marc Feldmann, Ewa Paleolog	2000	142
6	ZD6474, a Potent Inhibitor of Vascular Endothelial Growth Factor Signaling, Combined With Radiotherapy Clinical Cancer Research ·Kaye J. Williams, Brian A. Telfer, Sandra R. Brave, Jane Kendrew, Lynsey Whittaker, Ian J. Stratford, Stephen R. Wedge	2004	114
7	A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models Molecular Cancer Therapeutics ·Jeffrey L. Brown, Zhe Cao, Maria Pinzon-Ortiz, Jane Kendrew, Corinne Reimer, Shenghua Wen, Joe Q. Zhou, Mohammad Tabrizi, Steve Emery, Brenda McDermott, Lourdes Pablo, Patricia McCoon, Vahe Bedian, David C. Blakey	2010	113
8	Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy Clinical Cancer Research ·Neil R. Smith, Dawn Baker, Matthew R. Farren, Aurélien Pommier, Ruth Swann, Xin Wang, Sunita Mistry, Karen McDaid, Jane Kendrew, Chris Womack, Stephen R. Wedge, Simon T. Barry	2013	111
9	Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor Molecular Cancer Therapeutics ·David McKillop, E. A. Partridge, John Kemp, Mike P. Spence, Jane Kendrew, Sharon Barnett, Phillippa G. Wood, Petrina B. Giles, Andrew B. Patterson, Francis Bichat, Nicolas Guilbaud, T C Stephens	2005	109
10	Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours British Journal of Cancer ·D. Checkley, Jean Tessier, Jane Kendrew, John C. Waterton, Stephen R. Wedge	2003	102
11	ZM323881, a Novel Inhibitor of Vascular Endothelial Growth Factor‐Receptor‐2 Tyrosine Kinase Activity Microcirculation ·C.E. Whittles, Tristan Pocock, Stephen R. Wedge, Jane Kendrew, Laurent Hennequin, Steven J. Harper, David O. Bates	2002	75
12	A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo Oncogene ·Catherine A. Eberlein, Jane Kendrew, Karen McDaid, Avril Alfred, Jinsol Kang, Vivien N. Jacobs, Sarah J. Ross, Claire Rooney, Neil R. Smith, Julie L. Rinkenberger, Alex Cao, Adrian T. Churchman, John F. Marshall, Hazel M. Weir, Vahe Bedian, D C Blakey, Ian N. Foltz, Simon T. Barry	2012	74
13	Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family Molecular Cancer Therapeutics ·Sandra R. Brave, Kirsty Ratcliffe, Zena Wilson, Neil H. James, Sue Ashton, Anna Wainwright, Jane Kendrew, Philippa Dudley, Nicola Broadbent, Graham Sproat, Sian Taylor, Claire H. Barnes, Jeffrey C. Silva, Charles L. Farnsworth, Laurent Hennequin, Donald Ogilvie, Juliane M. Jürgensmeier, Masabumi Shibuya, Stephen R. Wedge, Simon T. Barry	2011	72
14	Inhibition of Vascular Endothelial Growth Factor-A Signaling Induces Hypertension: Examining the Effect of Cediranib (Recentin; AZD2171) Treatment on Blood Pressure in Rat and the Use of Concomitant Antihypertensive Therapy Clinical Cancer Research ·Jon Curwen, Helen Musgrove, Jane Kendrew, Graham H.P. Richmond, Donald Ogilvie, Stephen R. Wedge	2008	70
15	The angiogenic receptor KDR is widely distributed in human tissues and tumours and relocates intracellularly on phosphorylation. An immunohistochemical study Histopathology ·Moira Stewart, Helen Turley, Nathan P. Cook, Francesco Pezzella, G Pillai, Donald Ogilvie, S. A. Cartlidge, David Paterson, C G Copley, Jane Kendrew, Claire H. Barnes, Adrian L. Harris, Kevin C. Gatter	2003	65
16	Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts Molecular Cancer Therapeutics ·Neil R. Smith, Neil H. James, I Oakley, Anna Wainwright, C G Copley, Jane Kendrew, Lynsey Womersley, Juliane M. Jürgensmeier, Stephen R. Wedge, Simon T. Barry	2007	52
17	Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenografts Magnetic Resonance Imaging ·D. Checkley, Jean Tessier, Stephen R. Wedge, Michael Dukes, Jane Kendrew, Brenda J Curry, Brian Middleton, John C. Waterton	2003	48
18	MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo Molecular Cancer Therapeutics ·David W. Jenkins, Sarah J. Ross, Margaret H. Veldman-Jones, Ian N. Foltz, Brandon C. Clavette, Kathy Manchulenko, Cath Eberlein, Jane Kendrew, Philip Petteruti, Song Cho, Melissa Damschroder, Li Peng, Dawn Baker, Neil R. Smith, Hazel M. Weir, David C. Blakey, Vahe Bedian, Simon T. Barry	2012	47
19	Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast‐enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol) NMR in Biomedicine ·Daniel P. Bradley, Jean Tessier, D. Checkley, Hideto Kuribayashi, John C. Waterton, Jane Kendrew, Stephen R. Wedge	2007	34
20	An Antibody Targeted to VEGFR-2 Ig Domains 4-7 Inhibits VEGFR-2 Activation and VEGFR-2–Dependent Angiogenesis without Affecting Ligand Binding Molecular Cancer Therapeutics ·Jane Kendrew, Cath Eberlein, Brad Hedberg, Karen McDaid, Neil R. Smith, Hazel M. Weir, Stephen R. Wedge, David C. Blakey, Ian N. Foltz, Joe Q. Zhou, Jaspal S. Kang, Simon T. Barry	2011	30

About Jane Kendrew

Jane Kendrew is a scholar working on Immunology and Allergy, Oncology, Cancer Research, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 33 papers that have together received 2.7k indexed citations. Recurring topics across this work include Angiogenesis and VEGF in Cancer (22 papers), HER2/EGFR in Cancer Research (8 papers), PI3K/AKT/mTOR signaling in cancer (8 papers), Cancer, Hypoxia, and Metabolism (7 papers), Cell Adhesion Molecules Research (5 papers), Lung Cancer Treatments and Mutations (4 papers), Quinazolinone synthesis and applications (3 papers) and MRI in cancer diagnosis (3 papers). The work is most often cited by research in Oncology (1.1k citations), Cancer Research (561 citations), Molecular Biology (1.5k citations), Immunology and Allergy (133 citations) and Pulmonary and Respiratory Medicine (638 citations). Jane Kendrew has collaborated with scholars based in United Kingdom, France and Singapore. Frequent co-authors include Stephen R. Wedge, Laurent Hennequin, Jon Curwen, Donald Ogilvie, Elaine S. E. Stokes, Michael Dukes, Andrew P. Thomas, Brenda J Curry, P.F. Wadsworth and Helen Musgrove. Their work appears in journals such as Molecular Cancer Therapeutics, Clinical Cancer Research, Cancer Research, Bioorganic & Medicinal Chemistry Letters and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact